A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 563-568

  Tierney, G M ^a   Griffin, N R ^a   Stuart, R C ^b   Kasem, H ^b   Lynch, K P ^c   Lury, J T ^c   Brown, P D ^c   Millar, A W ^c   Steele, R J C ^d   Parsons, S L ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Gastric cancer; Histopathological effects; Marimastat; Metalloproteinase inhibitors

Indexed keywords

MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS TUMOR; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL DRUG ADMINISTRATION; PAIN; PILOT STUDY; PRIORITY JOURNAL; RIGIDITY; SKIN DISEASE; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; MIDDLE AGED; PILOT PROJECTS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0033119677     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00007-6     Document Type: Article

References (26)

1. Coggon D., Inskip H. Is there an epidemic of cancer? Br. Med. J. 308:1994;705-708.
2. Neugut Al., Hayek M., Howe G. Epidemiology of gastric cancer. Sem. Oncol. 23:1996;281-291.
3. Suvakovic Z., Bramble M.G., Jones R., Wilson C., Idle N., Ryott J. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut. 41:1997;308-313.
4. Cullinan S.A., Moertel C.G., Wieand H.S., et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12:1994;412-416.
5. Loehrer Sr P.J., Harry D., Chlebowski R.T. 5-fluorouracil vs epirubicin vs 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest. New Drugs. 12:1994;57-63.
6. Wilke H., Wils J., Rougier P., et al. Preliminary analysis of a randomised phase III trial of FAMTX versus ELF versus cisplatin/5-FU in advanced gastric cancer: a trial of the EORTC gastrointestinal tract cancer cooperative group and the AIO. Proc. Am. Soc. Clin. Oncol. 14:1995;206.
7. Cocconi G., DeLisi V., BiBlasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced cancer. Cancer Treat. Rep. 66:1982;1263-1266.
8. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genetics. 6:1990;121-125.
9. Liotta L.A., Stetler-Stevenson W.G. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1:1990;99-106.
10. Saarialho-Kere U.K., Vaalamo M., Puolakkainen P., Airola K., Parks W.C., Karjalainen-Lindsberg M.L. Enhanced expression of matrilysin, collagenase and stromelysin-1 in gastrointestinal ulcers. Am. J. Pathol. 148:1996;519-526.
11. Gordon J.L., Drummond A.H., Galloway W.A. Metalloproteinase inhibitors as therapeutics. Clin. Exp. Rheum. 11:1993;S91-S94.
12. O'Byrne E.M., Parker D.T., Roberts E.D., et al. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflamm. Res. 44:1995;S117-S118.
13. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
14. Rosenberg G.A. Matrix metalloproteinases in brain injury. J. Neurotrauma. 12:1995;833-842.
15. Grigioni W.F., D'Errico A., Fortunato C., et al. Prognosis of gastric carcinoma revealed by interactions between tumour cells and basement membrane. Mod. Pathol. 7:1994;220-225.
16. Honda M., Mori M., Ueo H., Sugimachi K., Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 39:1996;444-448.
17. Sier C.F., Kubben F.J., Ganesh S., et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer. 74:1996;413-417.
18. Torii A., Kodera Y., Uesaka K., et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br. J. Surg. 84:1997;133-136.
19. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6:1995;967-974.
20. Millar A.W., Brown P.D., Moore J., et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45:1998;21-26.
21. Davies B., Brown P.D., East N., Crimmin M.J., Balkwill F.R. A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. Cancer Research. 53:1993;2087-2091.
22. Neumanitis J., Poole C., Primrose J., et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer term studies. Clin. Cancer Res. 4:1998;1101-1109.
23. Primrose J.N., Bleiberg H., Daniel F., et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br. J. Cancer. 79:1999;509-514.
24. Wojtowicz-Praga S., Torri J., Johnson M., et al. Phase I trial of marimastat, a novel matrix-metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16:1998;2150-2156.
25. Bunker T.D., Anthony P.P. The pathology of frozen shoulder. A Dupuytren-like disease. J. Bone Joint Surg. 77:1995;677-683.
26. Sledge G.W., Qulali M., Goulet R., Bone E.A., Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Res. 87:1995;1546-1550.